These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22401863)

  • 1. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
    Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the UDP pocket of LpxC through amino acid analogs.
    Hale MR; Hill P; Lahiri S; Miller MD; Ross P; Alm R; Gao N; Kutschke A; Johnstone M; Prince B; Thresher J; Yang W
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2362-7. PubMed ID: 23499237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
    McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
    Pirrung MC; Tumey LN; McClerren AL; Raetz CR
    J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
    Montgomery JI; Brown MF; Reilly U; Price LM; Abramite JA; Arcari J; Barham R; Che Y; Chen JM; Chung SW; Collantes EM; Desbonnet C; Doroski M; Doty J; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; McAllister L; McElroy E; Menard CA; Mitton-Fry M; Mullins L; Noe MC; O'Donnell J; Oliver R; Penzien J; Plummer M; Shanmugasundaram V; Thoma C; Tomaras AP; Uccello DP; Vaz A; Wishka DG
    J Med Chem; 2012 Feb; 55(4):1662-70. PubMed ID: 22257165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
    McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
    Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of a carbohydrate-derived hydroxamic acid inhibitor of the bacterial enzyme (LpxC) involved in lipid A biosynthesis.
    Li X; Uchiyama T; Raetz CR; Hindsgaul O
    Org Lett; 2003 Feb; 5(4):539-41. PubMed ID: 12583763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent inhibitors of LpxC for the treatment of Gram-negative infections.
    Brown MF; Reilly U; Abramite JA; Arcari JT; Oliver R; Barham RA; Che Y; Chen JM; Collantes EM; Chung SW; Desbonnet C; Doty J; Doroski M; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; Marra A; McElroy E; Melnick M; Menard CA; Montgomery JI; Mullins L; Noe MC; O'Donnell J; Penzien J; Plummer MS; Price LM; Shanmugasundaram V; Thoma C; Uccello DP; Warmus JS; Wishka DG
    J Med Chem; 2012 Jan; 55(2):914-23. PubMed ID: 22175825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
    Piizzi G; Parker DT; Peng Y; Dobler M; Patnaik A; Wattanasin S; Liu E; Lenoir F; Nunez J; Kerrigan J; McKenney D; Osborne C; Yu D; Lanieri L; Bojkovic J; Dzink-Fox J; Lilly MD; Sprague ER; Lu Y; Wang H; Ranjitkar S; Xie L; Wang B; Glick M; Hamann LG; Tommasi R; Yang X; Dean CR
    J Med Chem; 2017 Jun; 60(12):5002-5014. PubMed ID: 28549219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis.
    Whittington DA; Rusche KM; Shin H; Fierke CA; Christianson DW
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8146-50. PubMed ID: 12819349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
    Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
    Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD
    Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide deformylase inhibitors with non-peptide scaffold: synthesis and structure-activity relationships.
    Lee SK; Choi KH; Lee SJ; Lee JS; Park JY; Kim BM; Lee BJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):133-6. PubMed ID: 21146987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
    Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
    Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refined solution structure of the LpxC-TU-514 complex and pKa analysis of an active site histidine: insights into the mechanism and inhibitor design.
    Coggins BE; McClerren AL; Jiang L; Li X; Rudolph J; Hindsgaul O; Raetz CR; Zhou P
    Biochemistry; 2005 Feb; 44(4):1114-26. PubMed ID: 15667205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.
    Cohen F; Aggen JB; Andrews LD; Assar Z; Boggs J; Choi T; Dozzo P; Easterday AN; Haglund CM; Hildebrandt DJ; Holt MC; Joly K; Jubb A; Kamal Z; Kane TR; Konradi AW; Krause KM; Linsell MS; Machajewski TD; Miroshnikova O; Moser HE; Nieto V; Phan T; Plato C; Serio AW; Seroogy J; Shakhmin A; Stein AJ; Sun AD; Sviridov S; Wang Z; Wlasichuk K; Yang W; Zhou X; Zhu H; Cirz RT
    ChemMedChem; 2019 Aug; 14(16):1560-1572. PubMed ID: 31283109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective mapping of chemical space for Pseudomonas aeruginosa deacetylase LpxC inhibitory potential.
    Kadam RU; Garg D; Roy N
    Chem Biol Drug Des; 2008 Jan; 71(1):45-56. PubMed ID: 18086152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.